ASND · Ascendis Pharma A/S

Ascendis Pharma’s Q1 2026 results mark a pivotal inflection point: the company transitioned from a pre-commercial R&D entity to a profitable, revenue-generating biopharma, with €247 million in total revenue — more than double Q1 2025’s €101 million. This growth was overwhelmingly driven by YORVIPATH, whose €197 million in revenue reflects strong U.S. uptake (>1,000 new patients in Q1) and expanded European access, while SKYTROFA contributed €44 million despite a modest year-over-year decline. The €25 million operating profit (versus a €104 million loss in Q1 2025) underscores improved operational leverage, though gross margin pressure is implied by rising SG&A (€145M vs. €101M) tied to global commercial expansion. Critically, the €629 million net profit includes a one-time €679 million benefit from recognizing previously unrecognized deferred tax assets — a non-cash accounting event that boosts GAAP earnings but does not reflect recurring profitability. Non-GAAP net profit of €18 million (€0.27 diluted EPS) better reflects underlying operations. Management highlighted three strategic pillars: sustained YORVIPATH momentum, successful U.S. launch of YUVIWEL (with >60 enrollments by May 1 and full orphan exclusivity through 2033), and disciplined capital allocation — evidenced by full conversion of $575M convertible notes into equity and the $187.5M PRV sale pending. The discontinuation of internal oncology development signals strategic focus on endocrinology rare diseases, aligning R&D spend with near-term commercial execution. Forward-looking commentary emphasized continued label expansions (PaTHway60, PaTHway Adolescent, reACHin), combination therapy progress (COACH Week 78/104 data), and expectation of EMA decision on YUVIWEL in Q4 2026.